About Mahmoud Gaballa, MBBCH
Dr. Gaballa completed his internal medicine residency training in Thomas Jefferson University Hospital. He then worked as a bone marrow transplant (BMT) hospitalist in Thomas Jefferson University Hospital. Dr. Gaballa then completed fellowship training in Hematology and Oncology at Baylor College of Medicine. He successfully received a T32 research grant and conducted several lab research projects focusing on chimeric antigen receptor T-cell (CAR-T) therapy and other cellular therapies. He then completed a second fellowship at MD Anderson Cancer Center focusing on cellular therapies and bone marrow transplantation. Finally, Dr. Gaballa joined MGH Cancer Center as faculty in the cellular immunotherapy program and bone marrow transplantation program.
Clinical Interests:
- Bone Marrow Transplantation
- Cellular Therapy (including CAR-T therapy)
Treats:
- Adult
Locations
Mass General Transplant Center
55 Fruit St.
Boston, MA 02114
Phone: 617-724-3456
Fax: 617-643-5843
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Gaballa?s research focuses on cellular therapies, including chimeric antigen receptor T-cell (CAR-T) therapy.
Publications
-
? Gaballa MR*, Banerjee P*, Milton DR, Jiang X, Ganesh C, Khazal S, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. (2021). Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood. [In Press]* Equal Contribution? Gaballa MR, Ma J, Tanner M, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. (2021). Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia & Lymphoma. DOI: 10.1080/10428194.2021.1992763. PMID: 34686083.? Gaballa MR, Kebriaei P. (2021). Advances in Cellular Immunotherapy in Hematologic Malignancies. Advances in Oncology. 2021;1:223-236. DOI: 10.1016/j.yao.2021.02.021? Jang A, Kram KN, Berger SN, Gaballa MR, Lu LB, Dunaway DR, Miller-Chism CN. (2020). Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compression: When Chemotherapy Alone Is Enough. Case Rep Med. doi:10.1155/2020/8735724. PMID: 32273896? Gaballa MR, Ramos CA. (2020). Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Current treatment options in oncology, 21(3), 21. doi:10.1007/s11864-020-0709-3? Gaballa M, Ramos, CA. (2019). ?Chapter 1: Overview of Normal Hematopoiesis? In Handbook of Benign Hematology, edited by Martha Pritchett Mims, Courtney Miller-Chism, Iberia Romina Sosa. ISBN-13 9780826149862.? Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, et al. (2016). Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget, 7(45), 72395-72414.? Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. (2015). Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk. Lymphoma 56, 3452?3454.? Gaballa MR, Besa E.C. (2014). Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann. Hematol. 93, 723?733.? Gaballa MR, Farag Y. (2013). Predictors of diabetic nephropathy. Open Med. 8, 287?296.? Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. (2012). Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev. Hematol. 5, 51?66; quiz 67?68.? Farag YM, Gaballa MR. (2011). Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 26(1):28-35. doi:10.1093/ndt/gfq576.